Depressive Symptoms, the Impact on ART Continuation, and Factors Associated with Symptom Improvement Among a Cohort of People Living with HIV in British Columbia, Canada.
British Columbia
Depressive symptoms
HIV care
HIV/AIDS
Mental health
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
26 Aug 2023
26 Aug 2023
Historique:
accepted:
10
08
2023
medline:
27
8
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
aheadofprint
Résumé
Depressive symptoms among people living with HIV (PLWH) are associated with poorer overall health outcomes. We characterized depressive symptoms and improvements in symptomology among PLWH (≥ 19 years old) in British Columbia (BC), Canada. We also examined associations between depressive symptomology and antiretroviral therapy (ART) treatment interruptions. Depressive symptoms were measured using the 10-item Center for Epidemiologic Studies Depression Scale (CES-D-10), within a longitudinal cohort study with three surveys administered 18-months apart. We used multivariable logistic regression to model factors associated with improvements in depressive symptoms (CES-D-10 scores from ≥ 10 to < 10). Of the 566 participants eligible for analysis 273 (48.2%) had CES-D scores indicating significant depressive symptoms (score ≥ 10) at enrollment. Improvements in symptoms at first follow-up were associated with greater HIV self-care on the Continuity of Care Scale (adjusted odds ratio: 1.17; 95% CI 1.03-1.32), and not having a previously reported mental health disorder diagnosis (aOR 2.86; 95% CI 1.01-8.13). Those reporting current cocaine use (aOR 0.33; 95% CI 0.12-0.91) and having a high school education, vs. less than, (aOR 0.25; 95% CI 0.08-0.82) had lower odds of improvement in depressive symptomatology. CES-D scores ≥ 10 were not significantly associated with ART treatment interruptions during follow-up (aOR: 1.08; 95% CI:0.65-1.8). Supporting greater self-care and consideration of mental health management strategies in relation to HIV may be useful in promoting the wellbeing of PLWH who experience depressive symptoms.
Identifiants
pubmed: 37632606
doi: 10.1007/s10461-023-04156-3
pii: 10.1007/s10461-023-04156-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health, British Columbia
ID : Ministry of Health, British Columbia
Organisme : British Columbia Centre for Excellence in HIV/AIDS
ID : British Columbia Centre for Excellence in HIV/AIDS
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15(1):1–10.
doi: 10.1186/s12879-015-0969-x
Kerkerian G, Kestler M, Carter A, Wang L, Kronfli N, Sereda P, et al. Attrition across the HIV cascade of care among a diverse cohort of women living with HIV in Canada. JAIDS. 2018;79(2):226–36.
pubmed: 29916960
Lourenco L, Colley G, Nosyk B, Shopin D, Montaner JS, Lima VD. High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. PLoS ONE. 2014;9(12):e115277.
pubmed: 25541682
pmcid: 4277297
doi: 10.1371/journal.pone.0115277
Jongbloed K, Pooyak S, Sharma R, Mackie J, Pearce ME, Laliberte N, et al. Experiences of the HIV Cascade of care among indigenous peoples: a systematic review. AIDS Behav. 2019;23(4):984–1003.
pubmed: 30600452
doi: 10.1007/s10461-018-2372-2
Rebeiro PF, Abraham AG, Horberg MA, Althoff KN, Yehia BR, Buchacz K, et al. Sex, race, and HIV risk disparities in discontinuity of HIV care after antiretroviral therapy initiation in the United States and Canada. AIDS Patient Care STDs. 2017;31(3):129–44.
pubmed: 28282246
pmcid: 5359655
doi: 10.1089/apc.2016.0178
Katz IT, Maughan-Brown B. Improved life expectancy of people living with HIV: who is left behind? The Lancet HIV. 2017;4(8):e324–e6.
pubmed: 28501496
pmcid: 5828160
doi: 10.1016/S2352-3018(17)30086-3
Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, et al. Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ Open. 2021;11(1):e041734.
pubmed: 33419911
pmcid: 7799128
doi: 10.1136/bmjopen-2020-041734
Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):1–11.
doi: 10.1007/s11920-014-0530-4
Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–30.
pubmed: 11329393
doi: 10.1176/appi.ajp.158.5.725
World Health Organization. Depression and other Common Mental Disorders: Global Health estimates. Geneva, Switzerland: World Health Organization; 2017.
Tran BX, Ho R, Ho CS, Latkin CA, Phan HT, Ha GH, et al. Depression among patients with HIV/AIDS: research development and effective interventions (GAPRESEARCH). Int J Environ Res Public Health. 2019;16(10):1772.
pubmed: 31109139
pmcid: 6571985
doi: 10.3390/ijerph16101772
Rezaei S, Ahmadi S, Rahmati J, Hosseinifard H, Dehnad A, Aryankhesal A, et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Supportive & Palliative Care. 2019;9(4):404–12.
Pence BW, O’Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656.
pubmed: 22398574
doi: 10.1097/QAD.0b013e3283519aae
Bengtson AM, Pence BW, Crane HM, Christopoulos K, Fredericksen RJ, Gaynes BN, et al. Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PLoS ONE. 2016;11(8):e0160738.
pubmed: 27513328
pmcid: 4981370
doi: 10.1371/journal.pone.0160738
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. JAIDS. 2011;58(2).
Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175–83.
pubmed: 17502728
doi: 10.1097/QAD.0b013e32811ebf57
Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11):1466–74.
pubmed: 11255423
doi: 10.1001/jama.285.11.1466
Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.
pubmed: 22644066
pmcid: 3481055
doi: 10.1007/s10461-012-0212-3
Rivera-Rivera Y, Vázquez-Santiago FJ, Albino E, Sánchez MdC, Rivera-Amill V. Impact of depression and inflammation on the progression of HIV disease. J Clin Cell Immunol. 2016;7(3).
Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. J Neuropsychiatry Clin Neurosci. 2014;68(2):96–109.
Effendy E, Amin MM, de Vega L, Utami N. The association between CD-4 level, stress and depression symptoms among people living with HIV/AIDS. Open access Macedonian Journal of Medical Sciences. 2019;7(20):3459.
pubmed: 32002074
pmcid: 6980827
doi: 10.3889/oamjms.2019.446
Armoon B, Fleury M-J, Bayat A-H, Fakhri Y, Higgs P, Moghaddam LF, et al. HIV related stigma associated with social support, alcohol use disorders, depression, anxiety, and suicidal ideation among people living with HIV: a systematic review and meta-analysis. Int J Mental Health Syst. 2022;16(1):1–17.
doi: 10.1186/s13033-022-00527-w
Rooney AS, Moore RC, Paolillo EW, Gouaux B, Umlauf A, Letendre SL, et al. Depression and aging with HIV: Associations with health-related quality of life and positive psychological factors. J Affect Disord. 2019;251:1–7.
pubmed: 30884371
pmcid: 6705595
doi: 10.1016/j.jad.2019.03.025
Bever A, Salters K, Tam C, Moore DM, Sereda P, Wang L et al. Cohort profile: the STOP HIV/AIDS program evaluation (SHAPE) study in British Columbia, Canada. BMJ Open. 2020;10(5).
British Columbia Ministry of Health. From Hope to Health: Towards an AIDS-free Generation. 2012.
Hogg RS, Heath KV, Yip B, Craib KJ, O’shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.
pubmed: 9466638
doi: 10.1001/jama.279.6.450
Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994;10(2):77–84.
pubmed: 8037935
doi: 10.1016/S0749-3797(18)30622-6
Zhang W, O’Brien N, Forrest JI, Salters KA, Patterson TL, Montaner JS, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS ONE. 2012;7(7):e40793.
pubmed: 22829885
pmcid: 3400644
doi: 10.1371/journal.pone.0040793
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.
doi: 10.1177/014662167700100306
Choi SK, Boyle E, Burchell AN, Gardner S, Collins E, Grootendorst P, et al. Validation of six short and ultra-short screening instruments for depression for people living with HIV in Ontario: results from the Ontario HIV treatment network cohort study. PLoS ONE. 2015;10(11):e0142706.
pubmed: 26566285
pmcid: 4643910
doi: 10.1371/journal.pone.0142706
Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Tropical Med Int Health. 2011;16(10):1297–313.
doi: 10.1111/j.1365-3156.2011.02828.x
Wang L, Min JE, Zang X, Sereda P, Harrigan RP, Montaner JS, et al. Characterizing human immunodeficiency virus antiretroviral therapy interruption and resulting disease progression using population-level data in British Columbia, 1996–2015. Clin Infect Dis. 2017;65(9):1496–503.
pubmed: 29048508
pmcid: 5850445
doi: 10.1093/cid/cix570
Health Canada. Canadian Community Health Survey, cycle 2.2, Nutrition (2004): income-related Household Food Security in Canada. Health Canada, Ottawa, Canada; 2007.
Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32(2):189–98.
pubmed: 17306727
doi: 10.1016/j.jsat.2006.08.002
Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–14.
pubmed: 2035047
doi: 10.1016/0277-9536(91)90150-B
Dolovich LR, Nair KM, Ciliska DK, Lee HN, Birch S, Gafni A, et al. The diabetes continuity of Care Scale: the development and initial evaluation of a questionnaire that measures continuity of care from the patient perspective. Health Soc Care Commun. 2004;12(6):475–87.
doi: 10.1111/j.1365-2524.2004.00517.x
Logie CH, Kennedy VL, Tharao W, Ahmed U, Loutfy MR. Engagement in and continuity of HIV care among african and caribbean black women living with HIV in Ontario, Canada. Int J STD AIDS. 2017;28(10):969–74.
pubmed: 27956646
doi: 10.1177/0956462416683626
Herek GM, Capitanio JP. Symbolic prejudice or fear of infection? A functional analysis of AIDS-related stigma among heterosexual adults. Basic Appl Soc Psychol. 1998;20(3):230–41.
doi: 10.1207/s15324834basp2003_5
Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale¶. Res Nurs Health. 2001;24(6):518–29.
pubmed: 11746080
doi: 10.1002/nur.10011
Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV + youth. J Adolesc Health. 2007;40(1):96–8.
pubmed: 17185215
doi: 10.1016/j.jadohealth.2006.08.001
Pruden H. In:. Two-Spirit Conversations & Work: subtle and at the same time radically different. APHA; 2019. APHA’s 2019 Annual Meeting and Expo (Nov 2-Nov 6).
Duggal M, Chakrapani V, Liberti L, Satyanarayna V, Varghese M, Singh P, et al. Acceptability of mobile phone-based nurse-delivered counseling intervention to improve HIV treatment adherence and self-care behaviors among HIV-positive women in India. AIDS Patient Care STDs. 2018;32(9):349–59.
pubmed: 30179531
pmcid: 6121177
doi: 10.1089/apc.2017.0315
Chou F-Y, Holzemer WL. Linking HIV/AIDS clients’ self-care with outcomes. J Assoc Nurses AIDS Care. 2004;15(4):58–67.
pubmed: 15296659
doi: 10.1177/1055329003255592
Tufts KA, Wessell J, Kearney T. Self-care behaviors of african american women living with HIV: a qualitative perspective. J Assoc Nurses AIDS Care. 2010;21(1):36–52.
pubmed: 19819168
doi: 10.1016/j.jana.2009.07.006
Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27(9):2154–60.
pubmed: 15333477
doi: 10.2337/diacare.27.9.2154
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2013.
doi: 10.1176/appi.books.9780890425596
Köhler S, Chrysanthou S, Guhn A, Sterzer P. Differences between chronic and nonchronic depression: systematic review and implications for treatment. Depress Anxiety. 2019;36(1):18–30.
pubmed: 30300454
doi: 10.1002/da.22835
Moroz N, Moroz I, D’Angelo MS, editors. Mental health services in Canada: barriers and cost-effective solutions to increase access. Healthcare Management Forum; 2020: SAGE Publications Sage CA: Los Angeles, CA.
Choi SK, Boyle E, Cairney J, Gardner S, Collins EJ, Bacon J, et al. Adequacy of mental health services for HIV-positive patients with depression: Ontario HIV Treatment Network Cohort Study. PLoS ONE. 2016;11(6):e0156652.
pubmed: 27280751
pmcid: 4900603
doi: 10.1371/journal.pone.0156652
Johnson JG, Rabkin JG, Lipsitz JD, Williams JB, Remien RH. Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Compr Psychiatr. 1999;40(1):31–4.
doi: 10.1016/S0010-440X(99)90073-1
Rood BA, McConnell EA, Pantalone DW. Distinct coping combinations are associated with depression and support service utilization in men who have sex with men living with HIV. Psychol Sex Orientat Gend Divers. 2015;2(1):96.
pubmed: 26042226
pmcid: 4450098
doi: 10.1037/sgd0000091
Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychol Addict Behav. 2013;27(4):1050.
pubmed: 23438250
doi: 10.1037/a0031044
Javanbakht M, Shoptaw S, Ragsdale A, Brookmeyer R, Bolan R, Gorbach PM. Depressive symptoms and substance use: changes overtime among a cohort of HIV-positive and HIV-negative MSM. Drug Alcohol Depend. 2020;207:107770.
pubmed: 31841750
doi: 10.1016/j.drugalcdep.2019.107770
Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, et al. Reduced use of illicit substances, even without abstinence, is associated with improved depressive symptoms among people living with HIV. JAIDS. 2018;79(3):283.
pubmed: 30036277
Shokoohi M, Bauer GR, Kaida A, Logie CH, Lacombe-Duncan A, Milloy MJ, et al. Patterns of social determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis. Addiction. 2019;114(7):1214–24.
pubmed: 30698902
pmcid: 6992379
doi: 10.1111/add.14566
Tapp C, Milloy M, Kerr T, Zhang R, Guillemi S, Hogg RS, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11(1):1–7.
doi: 10.1186/1471-2334-11-86
Kim J, Lee E, Park B-J, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: a nationwide study. Sci Rep. 2018;8(1):1–8.
Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8(4):277–87.
pubmed: 21989672
doi: 10.1007/s11904-011-0098-0
Sauceda JA, Johnson MO, Saberi P. Nonadherence as 4-day antiretroviral therapy interruptions: do depression and race/ethnicity matter as much in the modern antiretroviral therapy era? AIDS Behav. 2016;20(11):2624–8.
pubmed: 26767532
pmcid: 4945486
doi: 10.1007/s10461-015-1283-8
Tufano CS, Amaral RAd, Cardoso LRD, Malbergier A. The influence of depressive symptoms and substance use on adherence to antiretroviral therapy. A cross-sectional prevalence study. Sao Paulo Med J. 2014;133:179–86.
pubmed: 25250800
doi: 10.1590/1516-3180.2013.7450010
Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV–HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19(2):171–8.
pubmed: 24166726
doi: 10.3851/IMP2699
Borran M, Dashti-Khavidaki S, Khalili H. The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression. Expert Opin Pharmacother. 2021;22(9):1179–92.
pubmed: 33586560
doi: 10.1080/14656566.2021.1882419
Tam CWL, Bacani N, Wesseling T, Grieve S, Salters K, et al. editors. The Role of Peer Research Associates in Collecting Data in Longitudinal Health Surveys. Canadian Association for HIV Research Conference: Hope, Victories, and Perseverance beyond 2020; Quebec City, Quebec.